Our Projects

Project Aurora

Target identification for neurodegenerative diseases.

Project Blushwood

Repurposing tigilanol tiglate (EBC-46), a PKC-activating diterpenoid from the Australian blushwood tree, as an oncolytic agent for subcutaneous human cancers via intratumoral injection.

Project Lazarus

HIV latency reversal program leveraging tigilanol tiglate analog PKC modulators — the "shock and kill" strategy. Evolved from Project Blushwood (oncology) using the Stanford/UCLA breakthrough: Cs₂CO₃/MeOH selective deprotection enables scalable C13-diversification of TT scaffold. Lead compound SUW402 shows PKC-β Ki = 0.12 nM and ~90% HIV latency reversal in Jurkat-Latency cells. Aims to eradicate latent HIV reservoirs that persist despite ART.

Project Nova

High-throughput screening of kinase inhibitors.

Project Phoenix

AI-driven discovery of novel anti-inflammatory APIs.

Project Titan

Scalable manufacturing platform for tigilanol tiglate (EBC-46) and therapeutic analogs via phorbol semi-synthesis from globally available Croton tiglium seeds. Replaces extraction from rare Australian blushwood tree with a 12-step route (12% overall yield, >80% avg per step) producing >2.5g EBC-46. Simplified analogs achievable in just 4-6 steps. Key innovations: singlet oxygen ene flow photochemistry, rhenium-catalyzed allylic transposition, and stereoselective DMDO epoxidation.